Loading organizations...
Key people at Breakthrough Properties.
Breakthrough Properties is a Los Angeles, California-based life science real estate investment firm that acquires, develops, and operates specialized research and development facilities in major urban technology centers worldwide. The firm focuses on creating purpose-built laboratory environments designed to support the operational needs of both early-stage startups and multinational corporations operating across the biotechnology, pharmaceutical, agricultural, and nutritional sectors. Operating with a team of 69 employees, the organization successfully raised a $3 billion fund in 2022 to finance extensive life science commercial property development across the United States and Europe. The enterprise functions as a strategic joint venture backed by prominent industry partners including Tishman Speyer and Bellco Capital, while developing specific regional community projects such as One Canal in Cambridge, Massachusetts. Breakthrough Properties was founded in 2019 by Dan Belldegrun, Rebecka Belldegrun, and Arie Belldegrun.
Key people at Breakthrough Properties.
Breakthrough Properties is a global life science real estate investment and development firm formed as a joint venture between Tishman Speyer and Bellco Capital.[1][2][3] Its mission is to acquire, develop, and operate premium life science properties in leading urban technology centers worldwide, fostering innovation in biotechnology, pharma, academic research, agriculture, and nutrition through cross-sector collaboration.[1][2][3] The firm's investment philosophy emphasizes a user-driven approach, combining Tishman Speyer's global real estate expertise with Bellco Capital's biotechnology entrepreneurship to create flexible, high-quality environments with superior design, buildouts, and amenities that support scientific breakthroughs.[2][3] Key sectors include life sciences real estate across the U.S., U.K., and continental Europe, targeting biotech hubs with purpose-built developments, conversions, and core properties.[3] Breakthrough significantly impacts the startup ecosystem by providing tailored lab spaces, access to a Scientific Advisory Board, venture capital networks, and mentorship, with 70% of leasing secured via direct relationships with premier life science users.[3]
Breakthrough Properties was founded in 2019 as a joint venture between Tishman Speyer, a global real estate owner and developer with experience across four continents, and Bellco Capital, a biotechnology investment firm focused on transformative life sciences companies.[2][3][5] Key partners include Tishman Speyer's real estate platform and Bellco Capital's network of academic physicians, scientists, and entrepreneurs, led by an experienced management team skilled in life science real estate operations.[2][3] The firm's evolution has centered on expanding from its U.S. base to international markets, closing a $3 billion inaugural fund in 2022 for nearly six million square feet of assets, followed by a $430 million raise in its next fund to fuel growth across eight biopharma markets.[3]
Breakthrough Properties rides the explosive growth of the life sciences sector, capitalizing on surging demand for specialized real estate amid biotech innovation in therapies, agriculture, and nutrition.[1][3] Timing is ideal as urban tech centers face lab space shortages, with market forces like post-pandemic R&D acceleration and cross-sector convergence favoring purpose-built facilities over generic offices.[2][3] The firm influences the ecosystem by enabling collaboration between startups, pharma giants, and academia, creating "homes for scientific discovery" that accelerate breakthroughs and retain talent in key hubs.[1][2]
Breakthrough is poised to scale its portfolio with the recent $430M fund, targeting more developments in high-growth biopharma markets while deepening DEI initiatives for industry inclusivity.[2][3] Trends like AI-driven drug discovery and sustainable lab designs will shape its trajectory, amplifying demand for adaptive spaces.[2] Its influence may evolve into a dominant global platform, setting standards for life science real estate and powering the next wave of patient-impacting therapies—reaffirming its core mission to reimagine environments for innovation.[1][3]
